A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

FLAME-ASCVD-Nephro A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06322641

Enrollment

300

Registered

2024-03-21

Start date

2024-03-26

Completion date

2024-05-10

Last updated

2024-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Systemic Inflammation

Brief summary

The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD)

Interventions

OTHERNo treatment given

No treatment given

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Is a Nephrologist. * Has been in practice greater than or equal to 3 years. * Sees at least 20 patients with ASCVD and CKD per month. * Treats patients for more than only dialysis

Exclusion criteria

* Previous participation in this study. Participation is defined as having given informed consent in this study * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Does not meet inclusion criteria requirements

Design outcomes

Primary

Measure	Time frame	Description
Nephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD	At the time of survey response (Day 1)	Multi-select from a defined list; Numerical; A 7-point Likert scale for measurement of agreement from 1 strongly disagree to 7 strongly agree.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026